ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
